A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction
30 August 2024 (08:00 - 17:30)
Organised by: 
About the speaker
Novartis Biomedical Research, Cambridge (United States of America)
4 More presentations in this session
Doctor D. Birnie (Ottawa, CA)
Professor C. Sohns (Bad Oeynhausen, DE)
Rapid detection of incident heart failure by artificial intelligence: lessons from the NIL-CHF trial
Professor S. Stewart (Fremantle, AU)
Access the full session
The Event
ESC Congress 2024
30 August - 2 September 2024
